Merck Kgaa Unsp ADR (MKGAY) 28.8260 $MKGAY
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Cellular Imaging Market (Single Cell Analysis/Live Cell Imaging) Report 2014
M2 - Tue Jul 22, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b39q77/cellular_imaging) has announced the addition of the "Cellular Imaging Market (single cell analysis/Live cell imaging)" report to their offering. Single cell analysis plays an important role in genomics, proteomics, transcriptomics and epigenomics at the single cell level. It provides an ultra-sensitive tool to explicate specific molecular mechanisms and pathways and reveal the nature of cell heterogenecity. Hospitals, academic and government bodies, as well as pharmaceutical and biotechnology companies are mounting their focus on using cell analysis as a prevailing tool in research, drug discovery and diagnosis. The cell analysis market is mainly segmented into consumables and instruments. The consumables include reagents, assay plates and microplates. The instrument segment comprises of microscopes, flow cytometer, spectrophotometer, quantitative polymerase chain reaction (QPCR), microfluidic devices, cell counters, high content screening (HCS) systems and cell microarrays. Among the cell analysis products, the consumables market dominated the instruments market by occupying a largest share of more than 60%. However, the cell analysis instruments market is expected to grow at the highest CAGR. Geographical wise North America is the largest market, followed by Europe and Asia. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the cell analysis market. Growth in the Asian market is attributed to government for its support in establishing innovative screening technologies and increasing demand for outsourcing of drug discovery services. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/b3...ar_imaging
Merck KGaA's Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D
Business Wire - Mon Jul 14, 8:01AM CDT
Merck KGaA's biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment
PR Newswire - Thu Jul 10, 9:00AM CDT
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials.
International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019
M2 - Thu Jul 10, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3hzhj7/transfection) has announced the addition of the "International Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019" report to their offering. Transfection is a technique used to introduce nucleic acids (either DNA or RNA) into cells. This technology helps the cells to regulate gene therapy, mutation of cancer cells and protein metabolism by affecting the nuclear genes. The transfection technology market is driven by factors such as increasing demand for protein production, emerging biopharmaceutical market and rising prevalence of cancer and infectious diseases, globally. The report explains various advancements taking place in this market and analyses the global transfection technology market by types of methods and applications. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method. The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, catonic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection and laserfection.The transfection technology market has also been segmented on the basis of its application in biomedical research, therapeutic delivery (biotherapeutics and electro-chemotherapy and electro-immunotherapy) and protein production. Furthermore, the biomedical research segment includes transgenic models, cancer research, gene and protein expression studies and cell-based microarrays for drug discovery and development. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Transfection Technology Market, by Methods Chapter 5 Global Transfection Technology Market, By Application Chapter 6 Global Transfection Technology Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Bio-Rad Laboratories, Inc. - Harvard Bioscience, Inc. - Life Technologies Corporation - Lonza Group Ltd. - Merck KGaA - Mirus Bio LLC - Polyplus-transfection S.A. - Promega Corporation - QIAGEN - Roche Holding AG - Sigma-Aldrich Corporation - SignaGen Laboratories - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/3h...ansfection
EMD Serono Participates in Global Grants Program to Fund Scientific Innovation and Medical Education
Business Wire - Tue Jul 08, 8:01AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced its participation in the Merck Global Grants initiative - a program that underscores the company's commitment to funding scientific innovation via research grants and supporting medical education of healthcare providers and patients around the world. The initiative encompasses all of the various grants that EMD Serono offers, including its Grants for Innovation in Research, its Independent Medical Grants, and Grants for Medical Education of Healthcare Providers and Patients.
EMD Serono Commits EUR 2 million to the Grant for Fertility Innovation (GFI) for 2014 /15
PR Newswire - Tue Jul 01, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced its strong support of the Grant for Fertility Innovation (GFI) fund with grants totaling up to EUR 2 million for the years 2014/2015. The announcement was made during the 30th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) currently taking place in Munich.
Deciphera Pharmaceuticals Appoints Oliver Rosen M.D. as Chief Medical Officer
Business Wire - Mon Jun 30, 7:30AM CDT
Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments targeting the tumor microenvironment, today announced the appointment of Oliver Rosen, M.D., as Chief Medical Officer. Dr. Rosen will be responsible for leading the company's clinical development strategy and clinical operations which includes a pipeline of cancer therapeutics targeting kinases that play an important role in tumor communication with the surrounding tissue. Prior to joining Deciphera, Dr. Rosen held clinical positions in the oncology field at premier biopharmaceutical companies, including Millennium, Genentech, Amgen, Hoffman La Roche and Merck KGaA.
EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates
PR Newswire - Tue Jun 24, 6:30AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Mersana Therapeutics, Inc., Cambridge, Mass., U.S., announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site.
Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates
Business Wire - Tue Jun 24, 12:30AM CDT
--Mersana Therapeutics' Fleximer(R) technology to be leveraged to create multiple antibody-drug conjugates
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Wed Jun 18, 3:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mvpkt/viibryd_major) has announced the addition of the "Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014). Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Viibryd for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Viibryd (Vilazodone) 7 Appendix For more information visit http://www.researchandmarkets.com/research/5m...bryd_major
Dr. Annalisa Jenkins Joins Biothera's Board of Directors
Business Wire - Mon Jun 16, 8:01AM CDT
Biothera announced today that noted pharmaceutical executive Dr. Annalisa Jenkins, MBBS, MRCP has joined its Board of Directors.
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell
EMD Serono Launches Compassionate Corps Program to Reduce Cost of Fertility Treatment for Eligible Military Veterans and their Spouses
PR Newswire - Wed Jun 11, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany announced today its commitment to U.S. military veterans and their spouses with the introduction of the Compassionate Corps Program. Through the program, veterans and their spouses may be eligible to receive free fertility medicine.
Indolent Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sw248r/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Accentia Biopharmaceuticals, Inc. - Astellas Pharma Inc. - Bayer AG - Biogen Idec Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Merck & Co., Inc. - Merck KGaA - Pharmacyclics, Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/sw...t_lymphoma
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers
CNW Group - Thu May 29, 1:30AM CDT
ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552
Merck KGaA Presents Innovations at SID Display Week 2014
PR Newswire - Wed May 28, 3:30PM CDT
-- Keynote speech by Michael Heckmeier: Synergies are accelerating the development of ultra-modern materials for LC and OLED applications, permitting a broad portfolio of future-oriented technologies - not only for displays
True Diagnostics Signs Commercialization Agreement With Merck KGaA, Darmstadt, Germany
Marketwire - Wed May 28, 9:01AM CDT
True Diagnostics, Inc., a company dedicated to the discovery and development of innovative diagnostic solutions, announced today that they have entered into a collaboration with Merck KGaA, Darmstadt, Germany, a world leader in providing CardioMetabolic Care. Under the agreement, True Diagnostics will collaborate with the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada to help improve and increase access to Thyroid Care in the People's Republic of China. The partnership allows the companies to provide Medical Professionals with a new and meaningful point-of-care method for rapid screening hypothyroidism patients in minutes using only a small sample of whole-blood collected directly from the patient's fingertip.
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued Commitment to Patients with Relapsing MS
PR Newswire - Wed May 28, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Rebif® (interferon beta-1a) data will be presented at the 2014 Cooperative Meeting of CMSC (Consortium of Multiple Sclerosis Centers) and ACTRIMS (Americas Committee on Research & Treatment in Multiple Sclerosis), taking place from May 28 - 31, in Dallas, TX.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Cellular Imaging Market (Single Cell Analysis/Live Cell Imaging) Report 2014
M2 - Tue Jul 22, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b39q77/cellular_imaging) has announced the addition of the "Cellular Imaging Market (single cell analysis/Live cell imaging)" report to their offering. Single cell analysis plays an important role in genomics, proteomics, transcriptomics and epigenomics at the single cell level. It provides an ultra-sensitive tool to explicate specific molecular mechanisms and pathways and reveal the nature of cell heterogenecity. Hospitals, academic and government bodies, as well as pharmaceutical and biotechnology companies are mounting their focus on using cell analysis as a prevailing tool in research, drug discovery and diagnosis. The cell analysis market is mainly segmented into consumables and instruments. The consumables include reagents, assay plates and microplates. The instrument segment comprises of microscopes, flow cytometer, spectrophotometer, quantitative polymerase chain reaction (QPCR), microfluidic devices, cell counters, high content screening (HCS) systems and cell microarrays. Among the cell analysis products, the consumables market dominated the instruments market by occupying a largest share of more than 60%. However, the cell analysis instruments market is expected to grow at the highest CAGR. Geographical wise North America is the largest market, followed by Europe and Asia. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the cell analysis market. Growth in the Asian market is attributed to government for its support in establishing innovative screening technologies and increasing demand for outsourcing of drug discovery services. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/b3...ar_imaging
Merck KGaA's Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D
Business Wire - Mon Jul 14, 8:01AM CDT
Merck KGaA's biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment
PR Newswire - Thu Jul 10, 9:00AM CDT
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials.
International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019
M2 - Thu Jul 10, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3hzhj7/transfection) has announced the addition of the "International Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019" report to their offering. Transfection is a technique used to introduce nucleic acids (either DNA or RNA) into cells. This technology helps the cells to regulate gene therapy, mutation of cancer cells and protein metabolism by affecting the nuclear genes. The transfection technology market is driven by factors such as increasing demand for protein production, emerging biopharmaceutical market and rising prevalence of cancer and infectious diseases, globally. The report explains various advancements taking place in this market and analyses the global transfection technology market by types of methods and applications. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method. The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, catonic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection and laserfection.The transfection technology market has also been segmented on the basis of its application in biomedical research, therapeutic delivery (biotherapeutics and electro-chemotherapy and electro-immunotherapy) and protein production. Furthermore, the biomedical research segment includes transgenic models, cancer research, gene and protein expression studies and cell-based microarrays for drug discovery and development. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Transfection Technology Market, by Methods Chapter 5 Global Transfection Technology Market, By Application Chapter 6 Global Transfection Technology Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Bio-Rad Laboratories, Inc. - Harvard Bioscience, Inc. - Life Technologies Corporation - Lonza Group Ltd. - Merck KGaA - Mirus Bio LLC - Polyplus-transfection S.A. - Promega Corporation - QIAGEN - Roche Holding AG - Sigma-Aldrich Corporation - SignaGen Laboratories - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/3h...ansfection
EMD Serono Participates in Global Grants Program to Fund Scientific Innovation and Medical Education
Business Wire - Tue Jul 08, 8:01AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced its participation in the Merck Global Grants initiative - a program that underscores the company's commitment to funding scientific innovation via research grants and supporting medical education of healthcare providers and patients around the world. The initiative encompasses all of the various grants that EMD Serono offers, including its Grants for Innovation in Research, its Independent Medical Grants, and Grants for Medical Education of Healthcare Providers and Patients.
EMD Serono Commits EUR 2 million to the Grant for Fertility Innovation (GFI) for 2014 /15
PR Newswire - Tue Jul 01, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced its strong support of the Grant for Fertility Innovation (GFI) fund with grants totaling up to EUR 2 million for the years 2014/2015. The announcement was made during the 30th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) currently taking place in Munich.
Deciphera Pharmaceuticals Appoints Oliver Rosen M.D. as Chief Medical Officer
Business Wire - Mon Jun 30, 7:30AM CDT
Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments targeting the tumor microenvironment, today announced the appointment of Oliver Rosen, M.D., as Chief Medical Officer. Dr. Rosen will be responsible for leading the company's clinical development strategy and clinical operations which includes a pipeline of cancer therapeutics targeting kinases that play an important role in tumor communication with the surrounding tissue. Prior to joining Deciphera, Dr. Rosen held clinical positions in the oncology field at premier biopharmaceutical companies, including Millennium, Genentech, Amgen, Hoffman La Roche and Merck KGaA.
EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates
PR Newswire - Tue Jun 24, 6:30AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Mersana Therapeutics, Inc., Cambridge, Mass., U.S., announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site.
Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates
Business Wire - Tue Jun 24, 12:30AM CDT
--Mersana Therapeutics' Fleximer(R) technology to be leveraged to create multiple antibody-drug conjugates
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Wed Jun 18, 3:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mvpkt/viibryd_major) has announced the addition of the "Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014). Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Viibryd for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Viibryd (Vilazodone) 7 Appendix For more information visit http://www.researchandmarkets.com/research/5m...bryd_major
Dr. Annalisa Jenkins Joins Biothera's Board of Directors
Business Wire - Mon Jun 16, 8:01AM CDT
Biothera announced today that noted pharmaceutical executive Dr. Annalisa Jenkins, MBBS, MRCP has joined its Board of Directors.
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell
EMD Serono Launches Compassionate Corps Program to Reduce Cost of Fertility Treatment for Eligible Military Veterans and their Spouses
PR Newswire - Wed Jun 11, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany announced today its commitment to U.S. military veterans and their spouses with the introduction of the Compassionate Corps Program. Through the program, veterans and their spouses may be eligible to receive free fertility medicine.
Indolent Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sw248r/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Accentia Biopharmaceuticals, Inc. - Astellas Pharma Inc. - Bayer AG - Biogen Idec Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Merck & Co., Inc. - Merck KGaA - Pharmacyclics, Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/sw...t_lymphoma
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers
CNW Group - Thu May 29, 1:30AM CDT
ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552
Merck KGaA Presents Innovations at SID Display Week 2014
PR Newswire - Wed May 28, 3:30PM CDT
-- Keynote speech by Michael Heckmeier: Synergies are accelerating the development of ultra-modern materials for LC and OLED applications, permitting a broad portfolio of future-oriented technologies - not only for displays
True Diagnostics Signs Commercialization Agreement With Merck KGaA, Darmstadt, Germany
Marketwire - Wed May 28, 9:01AM CDT
True Diagnostics, Inc., a company dedicated to the discovery and development of innovative diagnostic solutions, announced today that they have entered into a collaboration with Merck KGaA, Darmstadt, Germany, a world leader in providing CardioMetabolic Care. Under the agreement, True Diagnostics will collaborate with the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada to help improve and increase access to Thyroid Care in the People's Republic of China. The partnership allows the companies to provide Medical Professionals with a new and meaningful point-of-care method for rapid screening hypothyroidism patients in minutes using only a small sample of whole-blood collected directly from the patient's fingertip.
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued Commitment to Patients with Relapsing MS
PR Newswire - Wed May 28, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Rebif® (interferon beta-1a) data will be presented at the 2014 Cooperative Meeting of CMSC (Consortium of Multiple Sclerosis Centers) and ACTRIMS (Americas Committee on Research & Treatment in Multiple Sclerosis), taking place from May 28 - 31, in Dallas, TX.
